Physician profile
Allison Bean
NPI 1205589678
$6,558.83
in general payments reported to CMS, 2019-2025
59 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,084 · 2023: $1,292 · 2024: $893 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,474.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.24 | 2022-2025 | |
| Sk Life Science, INC. | $381.21 | 2022-2023 | |
| Biogen, INC. | $326.02 | 2022-2023 | Vumerity, Avonex, Plegridy |
| Novartis Pharmaceuticals Corporation | $306.78 | 2022-2023 | |
| Lundbeck LLC | $300.68 | 2022-2025 | Rexulti, Vyepti |
| Emd Serono, INC. | $283.28 | 2022-2023 | Mavenclad |
| Inspire Medical Systems, INC. | $274.27 | 2024-2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $250.54 | 2022-2024 | Austedo, Ajovy |
| Amgen INC. | $233.62 | 2022-2025 | Repatha, Otezla, Aimovig |
| Biohaven Pharmaceutical Holding Company Ltd. | $195.86 | 2022 | |
| Pfizer INC. | $179.39 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $169.31 | 2022-2023 | Ongentys, Ingrezza |
| Kyowa Kirin, INC. | $161.65 | 2022-2023 | Nourianz |
| Axsome Therapeutics, INC. | $146.47 | 2022-2025 | Auvelity, Sunosi |
| Novo Nordisk INC | $142.10 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Bean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.